
West Pharmaceutical Posts 0.4% Revenue Growth and Launches $35M Savings Restructuring
West Pharmaceutical Services IncDescription
What this story covers
West Pharmaceutical's Q1 2025 10-Q reveals $698M net sales (up 0.4%, 2.1% organic), Proprietary Products driving biologics demand, but profits dip from restructuring charges. Strong $129M operating cash flow supports capex and buybacks; hedges manage currency/commodity risks amid stable strategy.
Story snapshot
CompanyWest Pharmaceutical Services Inc
TickerWST
VariantStandard detailed
Duration12:25
Filing type10-Q
PeriodQ1 2025
IndustryHealthcare & Pharmaceuticals
Accession0000105770-25-000036
Full Story Script
Content not available for this story.